An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase
- 1 August 2002
- journal article
- research article
- Published by Elsevier BV in American Journal Of Medicine
- Vol. 113 (2), 104-111
- https://doi.org/10.1016/s0002-9343(02)01160-9
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Prediction of benefit from carotid endar terectomy in individual patients: a risk-modelling studyThe Lancet, 1999
- Heterogeneity of the Baseline Risk within Patient Populations of Clinical Trials: A Proposed Evaluation AlgorithmAmerican Journal of Epidemiology, 1998
- Risk for Intracranial Hemorrhage after Tissue Plasminogen Activator Treatment for Acute Myocardial InfarctionAnnals of Internal Medicine, 1998
- Patient-Specific Predictions of Outcomes in Myocardial Infarction for Real-Time Emergency Use: A Thrombolytic Predictive InstrumentAnnals of Internal Medicine, 1997
- Selection of thrombolytic therapy for individual patients: Development of a clinical modelAmerican Heart Journal, 1997
- Can overall results of clinical trials be applied to all patients?The Lancet, 1995
- Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial InfarctionNew England Journal of Medicine, 1995
- Tailored thrombolytic therapy. A perspective.Circulation, 1993
- Markov Models in Medical Decision MakingMedical Decision Making, 1993
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993